| Literature DB >> 28819223 |
Shun-Ming Chan1,2,3, Bo-Feng Lin1,2,3, Chih-Shung Wong2,4, Wen-Ting Chuang1,3, Yu-Ting Chou5, Zhi-Fu Wu6,7,8.
Abstract
While anaesthetics are frequently used on cancer patients during surgical procedures, their consequence on cancer progression remains to be elucidated. In this study, we sought to investigate the influence of local anesthetics on lung cancer cell dissemination in vitro and in vivo. A549 human non-small lung cancer cells were treated with various local anaesthetics including ropivacaine, lidocaine, levobupivacaine and bupivacaine. Cell barrier property was assessed using an electric cell-substrate impedance sensing (ECIS) system. The epithelial-to-mesenchymal transition (EMT) of treated cells was studied by immunofluorescence staining. In vitro and in vivo cancer cell dissemination were investigated.Gene expression microarray and quantitative real-time PCR (qrt-PCR) assays were used to identify the genes responsible for levobupivacaine-mediated cancer cell dissemination.The results illustrated that only levobupivacaine induced EMT in the treated cells and also caused the dissemination of cancer cells in vitro. In addition, after intravenous injection, levobupivacaine encouraged cancer cell dissemination in vivo. Gene expression microarray, qrt-PCR and immunoblotting revealed that after levobupivacaine treatment, the hypoxia-inducible factor (HIF)- 2α gene was upregulated in cancer cells. Our findings suggest that levobupivacaine may induce A549 lung cancer cell dissemination both in vitro and in vivo. More specifically, HIF-2α signaling possibly contributes to levobupivacaine-mediated A549 lung cancer cell dissemination.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28819223 PMCID: PMC5561232 DOI: 10.1038/s41598-017-08885-z
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Effects of ropivacaine, lidocaine, bupivacaine and levobupivacaine on cell barrier function and EMT of A549 lung cancer cells. (A) Barrier function of lung cancer cells with and without local anaesthetics treatment as assessed by electric cell-substrate impedance sensing (ECIS). Measurements were performed at 4 kHz. (B) Effect of levobupivacaine on the morphology of A549 cells. Levobupivacaine treatment induced morphological change after 24 hr exposure. (C) Immunofluorescence staining of E-cadherin (E-cad), N-cadherin (N-cad) and vimentin for A549 cells treated with or without levobupivacaine. Ropi indicates ropivacaine; Lido indicates lidocaine; Bupi indicates bupivacaine, Levo indicates levobupivacaine; and Ctrl indicates control. Scale bar = 200 μm.
Figure 2Levobupivacaine induced migration and invasion in lung cancer cells. (A) Transwell migration test for A549 cells treated with or without levobupivacaine. Migratory cells were quantified. Each column represents the mean ± SD **P < 0.01. (B) Transwell invasion test for A549 cells treated with or without levobupivacaine. Invading cells were quantified. Each column represents the mean ± SD *P < 0.05. Levo indicates levobupivacaine and Ctrl indicates control.
Figure 3Levobupivacaine encouraged cancer cell dissemination in vivo. (A) IVIS imaging performed on nude mice after i.v. injection of A549luc cells treated with or without levobupivacaine (upper). Photographs of lungs harvested from xenografted mice (lower) (Day 86). (B) H&E staining for micro- or macro-nodules in the lungs of xenografted mice (left). Quantitative analysis for tumor nodules in the lungs of xenografted mice (right). Histologic examination revealed a higher proportion of tumor nodules in the levobupivacaine group than in the control group. Furthermore, the experimental group was associated with bigger tumor size. Levo indicates levobupivacaine and Ctrl indicates control.
Figure 4Levobupivacaine induced HIF-2α expression. (A) Q-PCR analysis of HIF-2α transcripts extracted from A549 cells treated with levobupivacaine for indicated periods. (4 and 24 hrs) (B) Q-PCR analysis to determine mRNA levels of HIF-1α, HIF-2α, Slug, Snail and Twist in A549 cells treated with or without levobupivacaine for 24 hrs. (C) Immunoblotting analysis for HIF2-α and N-cadherin expression in A549 cells under hypoxia and/or levobupivacaine treatment. (D) Transwell migration analysis for A549 cells infected with lentiviral RNA against HIF-2α (shHIF-2α) or Scramble (SC) followed by treatment with or without levobupivacaine. Levo indicates levobupivacaine and HIF indicates hypoxia-induced factor. EPAS1 (Endothelial PAS domain-containing protein 1 is also known as hypoxia-inducible factor-2alpha (HIF-2α).